Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
41
CYBQF Quote, Financials, Valuation and Earnings
Last price:
$1.39
Seasonality move
:
-0.77%
Day range:
$1.39 - $1.39
52-week range:
$1.03 - $1.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.42x
P/B ratio:
1.09x
Volume:
--
Avg. volume:
--
1-year change:
34.95%
Market cap:
$293.5M
Revenue:
$28.8M
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CYBQF
CYBERDYNE, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CYBQF
CYBERDYNE, Inc.
|
$1.39 | -- | $293.5M | -- | $0.00 | 0% | 10.42x |
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
PPTDF
PeptiDream Inc.
|
$12.80 | -- | $1.7B | 13.79x | $0.00 | 0% | 13.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.34 | -- | $483.2M | -- | $0.00 | 0% | 2.50x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.10 | $17.93 | $47.7B | 191.62x | $0.32 | 4.38% | 1.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CYBQF
CYBERDYNE, Inc.
|
1.1% | 0.743 | 1.09% | 4.04x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CYBQF
CYBERDYNE, Inc.
|
$2.9M | -$1.4M | -0.59% | -0.6% | -20.77% | -$512.8K |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
CYBERDYNE, Inc. vs. Competitors
-
Which has Higher Returns CYBQF or HLOSF?
Healios KK has a net margin of -18.69% compared to CYBERDYNE, Inc.'s net margin of -9751.87%. CYBERDYNE, Inc.'s return on equity of -0.6% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital CYBQFCYBERDYNE, Inc.44.13% -$0.01 $271.2M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About CYBQF or HLOSF?
CYBERDYNE, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that CYBERDYNE, Inc. has higher upside potential than Healios KK, analysts believe CYBERDYNE, Inc. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings CYBQFCYBERDYNE, Inc.0 0 0 HLOSFHealios KK0 0 0 -
Is CYBQF or HLOSF More Risky?
CYBERDYNE, Inc. has a beta of 0.530, which suggesting that the stock is 46.987% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock CYBQF or HLOSF?
CYBERDYNE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYBERDYNE, Inc. pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYBQF or HLOSF?
CYBERDYNE, Inc. quarterly revenues are $6.5M, which are larger than Healios KK quarterly revenues of $128.8K. CYBERDYNE, Inc.'s net income of -$1.2M is lower than Healios KK's net income of $3.8M. Notably, CYBERDYNE, Inc.'s price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYBERDYNE, Inc. is 10.42x versus 303.04x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYBQFCYBERDYNE, Inc.10.42x -- $6.5M -$1.2M HLOSFHealios KK303.04x -- $128.8K $3.8M
-
Which has Higher Returns CYBQF or PPTDF?
PeptiDream Inc. has a net margin of -18.69% compared to CYBERDYNE, Inc.'s net margin of -25.38%. CYBERDYNE, Inc.'s return on equity of -0.6% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital CYBQFCYBERDYNE, Inc.44.13% -$0.01 $271.2M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About CYBQF or PPTDF?
CYBERDYNE, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CYBERDYNE, Inc. has higher upside potential than PeptiDream Inc., analysts believe CYBERDYNE, Inc. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYBQFCYBERDYNE, Inc.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is CYBQF or PPTDF More Risky?
CYBERDYNE, Inc. has a beta of 0.530, which suggesting that the stock is 46.987% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock CYBQF or PPTDF?
CYBERDYNE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYBERDYNE, Inc. pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYBQF or PPTDF?
CYBERDYNE, Inc. quarterly revenues are $6.5M, which are smaller than PeptiDream Inc. quarterly revenues of $29.3M. CYBERDYNE, Inc.'s net income of -$1.2M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, CYBERDYNE, Inc.'s price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYBERDYNE, Inc. is 10.42x versus 13.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYBQFCYBERDYNE, Inc.10.42x -- $6.5M -$1.2M PPTDFPeptiDream Inc.13.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns CYBQF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -18.69% compared to CYBERDYNE, Inc.'s net margin of -24.76%. CYBERDYNE, Inc.'s return on equity of -0.6% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital CYBQFCYBERDYNE, Inc.44.13% -$0.01 $271.2M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About CYBQF or SOLTF?
CYBERDYNE, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CYBERDYNE, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe CYBERDYNE, Inc. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CYBQFCYBERDYNE, Inc.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is CYBQF or SOLTF More Risky?
CYBERDYNE, Inc. has a beta of 0.530, which suggesting that the stock is 46.987% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock CYBQF or SOLTF?
CYBERDYNE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYBERDYNE, Inc. pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYBQF or SOLTF?
CYBERDYNE, Inc. quarterly revenues are $6.5M, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. CYBERDYNE, Inc.'s net income of -$1.2M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, CYBERDYNE, Inc.'s price-to-earnings ratio is -- while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYBERDYNE, Inc. is 10.42x versus 2.50x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYBQFCYBERDYNE, Inc.10.42x -- $6.5M -$1.2M SOLTFNxera Pharma Co., Ltd.2.50x -- $45.8M -$11.3M
-
Which has Higher Returns CYBQF or STMM?
Stemcell Holdings, Inc. has a net margin of -18.69% compared to CYBERDYNE, Inc.'s net margin of --. CYBERDYNE, Inc.'s return on equity of -0.6% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CYBQFCYBERDYNE, Inc.44.13% -$0.01 $271.2M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About CYBQF or STMM?
CYBERDYNE, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CYBERDYNE, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe CYBERDYNE, Inc. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYBQFCYBERDYNE, Inc.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is CYBQF or STMM More Risky?
CYBERDYNE, Inc. has a beta of 0.530, which suggesting that the stock is 46.987% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CYBQF or STMM?
CYBERDYNE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYBERDYNE, Inc. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYBQF or STMM?
CYBERDYNE, Inc. quarterly revenues are $6.5M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. CYBERDYNE, Inc.'s net income of -$1.2M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, CYBERDYNE, Inc.'s price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYBERDYNE, Inc. is 10.42x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYBQFCYBERDYNE, Inc.10.42x -- $6.5M -$1.2M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns CYBQF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of -18.69% compared to CYBERDYNE, Inc.'s net margin of -1.05%. CYBERDYNE, Inc.'s return on equity of -0.6% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital CYBQFCYBERDYNE, Inc.44.13% -$0.01 $271.2M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About CYBQF or TAK?
CYBERDYNE, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 18.6%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than CYBERDYNE, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than CYBERDYNE, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYBQFCYBERDYNE, Inc.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is CYBQF or TAK More Risky?
CYBERDYNE, Inc. has a beta of 0.530, which suggesting that the stock is 46.987% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock CYBQF or TAK?
CYBERDYNE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.38% to investors and pays a quarterly dividend of $0.32 per share. CYBERDYNE, Inc. pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.
-
Which has Better Financial Ratios CYBQF or TAK?
CYBERDYNE, Inc. quarterly revenues are $6.5M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. CYBERDYNE, Inc.'s net income of -$1.2M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, CYBERDYNE, Inc.'s price-to-earnings ratio is -- while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 191.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYBERDYNE, Inc. is 10.42x versus 1.63x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYBQFCYBERDYNE, Inc.10.42x -- $6.5M -$1.2M TAKTakeda Pharmaceutical Co., Ltd.1.63x 191.62x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
